MedTrace Logo

Impact of Anti-platelet Drug Exposure on Platelet mRNA Splicing in Healthy Subjects

NCT04088123 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2021-10-28

No results posted yet for this study

Summary

The purpose of this pilot study is to determine how the anti-platelet drug, ticagrelor, impacts platelet mRNA splicing after a single loading dose in 10 healthy participants. These results will be valuable in that they will help inform our analysis of platelet RNA splicing after a thrombotic event.

Conditions

  • Thrombosis; Artery

Interventions

DRUG

Ticagrelor Oral Tablet [Brilinta]

A single loading dose of ticagrelor (180 mg) will be administered to each participant in this study.

Sponsors & Collaborators

  • National Institute on Minority Health and Health Disparities (NIMHD)

    collaborator NIH

  • Shenandoah University

    collaborator OTHER

  • The GW Medical Faculty Associates

    collaborator OTHER

  • George Washington University

    lead OTHER

Principal Investigators

  • Travis J O'Brien, PHD · George Washington University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2020-09-23
Completion
2020-09-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04088123 on ClinicalTrials.gov